Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2016 | 1 |
2020 | 1 |
2021 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients.
Cell Rep Med. 2023 Jun 20;4(6):101079. doi: 10.1016/j.xcrm.2023.101079. Epub 2023 May 23.
Cell Rep Med. 2023.
PMID: 37327781
Free PMC article.
Sensory integration functions of children with cochlear implants.
Koester AC, Mailloux Z, Coleman GG, Mori AB, Paul SM, Blanche E, Muhs JA, Lim D, Cermak SA.
Koester AC, et al.
Am J Occup Ther. 2014 Sep-Oct;68(5):562-9. doi: 10.5014/ajot.2014.012187.
Am J Occup Ther. 2014.
PMID: 25184469
Item in Clipboard
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
Ogasawara K, Newhall K, Maxwell SE, Dell'Aringa J, Komashko V, Kilavuz N, Delarue R, Czuczman M, Sternas L, Rose S, Beach CL, Novick S, Zhou S, Palmisano M, Li Y.
Ogasawara K, et al.
Clin Pharmacokinet. 2020 Feb;59(2):217-227. doi: 10.1007/s40262-019-00804-x.
Clin Pharmacokinet. 2020.
PMID: 31332669
Free PMC article.
A decrease in durvalumab clearance over time was mainly explained by incorporation of time-dependent changes in albumin (in all patients) and immunoglobulin G (in patients with multiple myeloma) into the model. For multiple myeloma, patients with immunoglobulin G 20 g/L sh …
A decrease in durvalumab clearance over time was mainly explained by incorporation of time-dependent changes in albumin (in all patients) an …
Item in Clipboard
Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis.
D'Amora P, Silva IDCG, Tewari KS, Bristow RE, Cappuccini F, Evans SS, Salzgeber MB, Addis-Bernard PJ, Palma AM, Marchioni DML, Carioca AAF, Penner KR, Alldredge J, Longoria T, Nagourney RA.
D'Amora P, et al.
Gynecol Oncol. 2021 Oct;163(1):162-170. doi: 10.1016/j.ygyno.2021.08.001. Epub 2021 Aug 24.
Gynecol Oncol. 2021.
PMID: 34446269
Free article.
Item in Clipboard
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, Awada A, Berlière M, Amant F, Levine E, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF.
Limentani SA, et al.
Breast Cancer Res Treat. 2016 Apr;156(2):319-30. doi: 10.1007/s10549-016-3751-x. Epub 2016 Mar 18.
Breast Cancer Res Treat. 2016.
PMID: 26993131
Clinical Trial.
Item in Clipboard
Engaging Stakeholders to Develop a Roadmap for Dry Eye and MGD PCORI-Funded Research.
Warren NA, Maskin SL, Gurupur V, Rector DA, Adelman D, Howell S, McAree J, Dibble R, Carlisano C, Maconi DP, Schrotenboer D, Jaimes M, Marte N, Carlisano T, Toland C, Chung J, Cremers SL, Corbin GS.
Warren NA, et al.
Patient Relat Outcome Meas. 2024 May 12;15:143-186. doi: 10.2147/PROM.S438290. eCollection 2024.
Patient Relat Outcome Meas. 2024.
PMID: 38764936
Free PMC article.
Item in Clipboard
Cite
Cite